[Clinical Analysis of Mitoxantrone Liposome in the Treatment of Children with High-Risk Acute Myeloid Leukemia].

作者：Yuqing Jiao, Hao Xiong, Zhi Chen, Li Yang, Tao Fang, Ming Sun, Shanshan Qi, Wenjie Lu, Zhuo Wang, Yu Du, Linlin Luo · 发表于：PubMed · 年份：2024 · DOI：10.19746/j.cnki.issn.1009-2137.2024.02.006 · 被引用次数：3 · 研究领域：Medicine、Oncology、Internal medicine、Cancer research、Chemistry、Biochemistry

OBJECTIVE: To investigate the safety and efficacy of mitoxantrone liposome in the treatment of children with high-risk acute myeloid leukemia (AML). METHODS: The children with high-risk AML who received the mitoxantrone liposome regimen at Wuhan Children's Hospital from January 2022 to February 2023 were collected as the observation group, and the children with high-risk AML who received idarubicin regimen were enrolled as controls, and their clinical data were analyzed. Time to bone marrow recovery, the complete remission rate of bone marrow cytology, the clearance rate of minimal residual disease, and treatment-related adverse reactions were compared between the two groups. RESULTS: >0.05). The overall response rate of the two groups of patients was similar. CONCLUSION: The efficacy of mitoxantrone liposome is not inferior to that of idarubicin in children with high-risk AML, but mitoxantrone liposome allows a significantly shorter duration of bone marrow suppression and the safety is better.